6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 117 of the 118 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These findings have informed clinical practice guidelines and policy, which now recommend that SMBG not be used routinely in this group (21–26).”
In the citing paper
“While the drug manufacturer is currently offering a savings card program for some patients for whom pricing is a barrier, payor coverage for tirzepatide will likely be a barrier to patient use, especially before tirzepatide has been officially recognized as a standard of care in professional guidelines. 2”
From Tirzepatide: Clinical review of the twincretin injectable (2023) · cites this paper as [2]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“33% with metformin as initial pharmacotherapy) and in all-cause mortality (13% and 27%, respectively) (33).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Research works printed but not linked: 1
- Dicembrini, Impact of technology on glycemic control in type 2 diabetes: a meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion, Diabetes Obes Metab
Cited by
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
Diabetic foot ulcers: Classification, risk factors and management
Wang, X., Yuan, C.-X., Xu, B., & Yu, Z. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i12.1049 · Cited by 305
Yun, J.-S., & Ko, S.-H. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154838 · Cited by 292
Diabetic neuropathy: cutting-edge research and future directions
Yang, Y., Zhao, B., Wang, Y., Lan, H., Liu, X., Hu, Y., & Cao, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02175-1 · Cited by 234
Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users
Silva, J. D., Lepore, G., Battelino, T., Arrieta, A., Castañeda, J., Grossman, B., Shin, J., & Cohen, O. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0203 · Cited by 229
Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes
The GRADE Study Research Group (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200433 · Cited by 222
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
“The American Diabetes Association suggests using similar targets as for other types of diabetes, aiming to individualize glycemic control according to patient-specific factors including life expectancy, comorbidities, compliance, and risk of hypo-glycemia (402).”
BackgroundESO Guideline on covert cerebral small vessel disease
Wardlaw, J. M., Debette, S., Jokinen, H., De Leeuw, F.-E., Pantoni, L., Chabriat, H., Staals, J., Doubal, F., Rudilosso, S., Eppinger, S., et al. (2021) · European Stroke Journal · doi:10.1177/23969873211012132 · Cited by 168
RetractedHypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention
Nakhleh, A., & Shehadeh, N. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i12.2036 · Cited by 154
Optimized glycemic control of type 2 diabetes with reinforcement learning: a proof-of-concept trial
Wang, G., Liu, X., Ying, Z., Yang, G., Chen, Z., Liu, Z., Zhang, M., Yan, H., Lu, Y., Gao, Y., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02552-9 · Cited by 156
“WTR indicates the blood glucose value within the target range 3.9–10.0 mmol L −1 for each timepoint 5,26 .”
BackgroundInfluentialArrieta, A., Battelino, T., Scaramuzza, A. E., Da Silva, J., Castañeda, J., Cordero, T. L., Shin, J., & Cohen, O. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14714 · Cited by 154
Type 1 diabetes mellitus: much progress, many opportunities
Powers, A. C. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142242 · Cited by 152
Lip, G. Y. H., Lane, D. A., Lenarczyk, R., Boriani, G., Doehner, W., Benjamin, L. A., Fisher, M., Lowe, D., Sacco, R. L., Schnabel, R. B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac245 · Cited by 175
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
Song, Y., Zhao, Y., Shu, Y., Zhang, L., Cheng, W., Wang, L., Shu, M., Xue, B., Wang, R., Feng, Z., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1100453 · Cited by 141
Glycaemic management in diabetes: old and new approaches
Ceriello, A., Prattichizzo, F., Phillip, M., Hirsch, I. B., Mathieu, C., & Battelino, T. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00245-x · Cited by 139
Boughton, C. K., Tripyla, A., Hartnell, S., Daly, A., Herzig, D., Wilinska, M. E., Czerlau, C., Fry, A., Bally, L., & Hovorka, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01453-z · Cited by 125
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Mende, C. W. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01994-2 · Cited by 147
Personalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121
New horizons. A new paradigm for treating to target with second-generation obesity medications
Garvey, W. T. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab848 · Cited by 110
A practical guide for the management of steroid induced hyperglycaemia in the hospital
Aberer, F., Hochfellner, D. A., Sourij, H., & Mader, J. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102154 · Cited by 110
Predictors of time in target glucose range in real‐world users of the MiniMed 780G system
Castañeda, J., Mathieu, C., Aanstoot, H., Arrieta, A., Da Silva, J., Shin, J., & Cohen, O. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14807 · Cited by 106
Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring
Jackson, M. A., Ahmann, A., & Shah, V. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0007 · Cited by 106
Modifiable Risk Factors in Alzheimer Disease and Related Dementias: A Review
Litke, R. R., Garcharna, L. C., Jiwani, S., & Neugroschl, J. A. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.05.006 · Cited by 132
Paolisso, P., Foà, A., Bergamaschi, L., Angeli, F., Fabrizio, M., Donati, F., Toniolo, S., Chiti, C., Rinaldi, A., Stefanizzi, A., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01384-6 · Cited by 118
Wang, C., Yen, H., Lu, W., Ho, H.-H., Lin, W., Kuo, Y., Huang, Y.-Y., Tsai, S., & Lin, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.754401 · Cited by 125
Boye, K. S., Thieu, V. T., Lage, M. J., Miller, H., & Paczkowski, R. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02106-4 · Cited by 99
Colom, C., Rull, A., Sánchez‐Quesada, J. L., & Pérez, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081798 · Cited by 119
César, M. J. P., Molina‐Vega, M., Suárez-Arana, M., González‐Mesa, E., Sola-Moyano, A. P., Roldan-López, R., Romero-Narbona, F., Olveira, G., Tinahones, F. J., & González‐Romero, S. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.04.229 · Cited by 112
Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
Williams, D. M., Jones, H. F., & Stephens, J. W. (2022) · Dove Medical Press (Taylor and Francis Group) · Cited by 99
Pοlyzos, S. A., Kechagias, S., & Tsochatzis, E. A. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16575 · Cited by 99
Beato-Víbora, P. I., Gallego-Gamero, F., Ambrojo-López, A., Gil-Poch, E., Martín-Romo, I., & Arroyo-Díez, F. J. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0037 · Cited by 87
“20,21 The percentage of individuals who achieved both recommendations, a TIR 70–180 mg/dL > 70% and a time 70 mg/dL 4%, increased from 31% at baseline to 60% at the 1-month evaluation.”
Bergenstal, R. M., Mullen, D. M., Strock, E., Johnson, M. L., & Xi, M. X. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108106 · Cited by 87
Gilbert, T. R., Noar, A., Blalock, O., & Polonsky, W. H. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0666 · Cited by 81
Akyirem, S., Ekpor, E., Namumbejja Abwoye, D., Batten, J., & Nelson, L. E. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110774 · Cited by 80
Adane, T., Melku, M., Worku, Y. B., Fasil, A., Aynalem, M., Kelem, A., & Getawa, S. (2023) · Journal of Diabetes Research · doi:10.1155/2023/3117396 · Cited by 99
“Furthermore, recent blood transfusion, use of erythropoiesis-stimulating drugs, end-stage kidney disease, and pregnancy may cause discrepancies between the HbA1C result and the patient’s true mean glycaemia [59].”
BackgroundJiao, X., Shen, Y., & Chen, Y. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002633 · Cited by 76
Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes
Messer, L. H., Berget, C., Pyle, L., Vigers, T., Cobry, E., Driscoll, K. A., & Forlenza, G. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0165 · Cited by 76
Optimal Medical Management of Asymptomatic Carotid Stenosis
Hackam, D. G. (2021) · Stroke · doi:10.1161/strokeaha.120.033994 · Cited by 80
Missed and Mistimed Insulin Doses in People with Diabetes: A Systematic Literature Review
Robinson, S., Newson, R. S., Liao, B., Kennedy-Martin, T., & Battelino, T. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0164 · Cited by 73
“63,64 In the management of diabetes, it is important to move away from historical data review and response to an ever-changing clinical situation and move toward dynamic, (near) real-time behavioral changes.”
Ceriello, A., Lucisano, G., Prattichizzo, F., Grotta, R. L., Franzén, S., Svensson, A., Eliasson, B., & Nicolucci, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01445-4 · Cited by 88
Sinning, C., Makarova, N., Völzke, H., Schnabel, R. B., Ojeda, F., Dörr, M., Felix, S. B., Köenig, W., Peters, A., Rathmann, W., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01413-4 · Cited by 83
Frei, T., Chang, C.-H., Filo, M., Arampatzis, A., & Khammash, M. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2122132119 · Cited by 86
Dehghani Zahedani, A., Shariat Torbaghan, S., Rahili, S., Karlin, K., Scilley, D., Thakkar, R., Saberi, M., Hashemi, N., Perelman, D., Aghaeepour, N., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01081-3 · Cited by 62
Butt, M. D., Ong, S. C., Wahab, M. U., Rasool, M. F., Saleem, F., Hashmi, A., Sajjad, A., Chaudhry, F. A., & Babar, Z. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912611 · Cited by 93
Epidemiology of Type 1 Diabetes
Vanderniet, J. A., Jenkins, A. J., & Donaghue, K. C. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01762-w · Cited by 109
Evans, M., Welsh, Z., & Seibold, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01253-9 · Cited by 67
Prevention and Management Strategies for Diabetic Neuropathy
Smith, S., Normahani, P., Lane, T. R. A., Hohenschurz‐Schmidt, D., Oliver, N. S., & Davies, A. H. (2022) · Life · doi:10.3390/life12081185 · Cited by 99
Godoi, A., Reis Marques, I., Padrão, E. M. H., Mahesh, A., Hespanhol, L. C., Riceto Loyola Júnior, J. E., de Souza, I. A. F., Moreira, V. C. S., Silva, C. H., Miyawaki, I. A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01144-4 · Cited by 67
Alhaddad, A. Y., Aly, H., Gad, H., Al-Ali, A. K., Sadasivuni, K. K., Cabibihan, J., & Malik, R. A. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.876672 · Cited by 77
“…are clear American Diabetes Association (ADA) clinical practice recommendations to achieve optimal blood glucose targets using different therapies (American Diabetes Association, 2020a; American Diabetes Association, 2020b), but are inherently associated with an increased risk of hypoglycemia…”
BackgroundHandelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Rosenstock, J., Emral, R., Sauque-Reyna, L., Mohan, V., Trescolí, C., Al Sifri, S., Lalic, N., Alvarez, A., Picard, P., Bonnemaire, M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0393 · Cited by 63
The Use of Continuous Glucose Monitors in Sport: Possible Applications and Considerations.
Bowler, A.-L. M., Whitfield, J., Marshall, L., Coffey, V. G., Burke, L., & Cox, G. (2022) · International Journal of Sport Nutrition & Exercise Metabolism · doi:10.1123/ijsnem.2022-0139 · Cited by 65
Luo, Y., Wang, J., Sun, L. D., Gu, W., Zong, G., Song, B., Shen, C., Zhou, P., Chen, Y., Wu, Y., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac303 · Cited by 71
Tanabe, H., Masuzaki, H., & Shimabukuro, M. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109067 · Cited by 62
Palanca, A., van Nes, F., Pardo, F., Ampudia Blasco, F. J., & Mathieu, C. (2022) · Diabetes Care · doi:10.2337/dc21-1584 · Cited by 57
Vargas‐Vázquez, A., Bello‐Chavolla, O. Y., Ortíz‐Brizuela, E., Campos-Muñoz, A., Mehta, R., Villanueva-Reza, M., Bahena-López, J. P., Antonio‐Villa, N. E., González-Lara, M. F., Ponce‐de‐León, A., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002026 · Cited by 63
Associations between multiple heavy metals exposure and glycated hemoglobin in a Chinese population
Cai, J., Li, Y., Liu, S., Liu, Q., Xu, M., Zhang, J., Wei, Y., Mo, X., Lin, Y., Tang, X. A., et al. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.132159 · Cited by 58
Pei, J., Wang, X., Pei, Z., & Hu, X. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02026-9 · Cited by 72
“%) for those with a history of severe hypoglycemia, limited life expectancy, and advanced microvascular or macrovascular complications [33, 34].”
BackgroundZhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01198-4 · Cited by 55
Tundidor, D., Meek, C. L., Yamamoto, J. M., Martínez-Brú, C., Gich, I. J., Feig, D. S., Murphy, H. R., Corcoy, R., On Behalf of the CONCEPTT Collaborative Group, Murphy, H. R., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0073 · Cited by 63
Chen, J., Yin, D., & Dou, K. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01875-8 · Cited by 84
Diabetes and Progression of Heart Failure
Echouffo-Tcheugui, J. B., Ndumele, C. E., Zhang, S., Florido, R., Matsushita, K., Coresh, J., Skali, H., Shah, A. M., & Selvin, E. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.378 · Cited by 54
Galindo, R. J., Ali, M. K., Funni, S. A., Dodge, A. B., Kurani, S. S., Shah, N. D., Umpierrez, G. E., & McCoy, R. G. (2022) · Diabetes Care · doi:10.2337/dc21-1579 · Cited by 53
Jude, E. B., Malecki, M. T., Gomez Huelgas, R., Prazny, M., Snoek, F., Tankova, T., Giugliano, D., & Khunti, K. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01222-2 · Cited by 52
Zhang, A., Wang, J., Wan, X., Zhang, Z., Zhao, S., Guo, Z., & Wang, C. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19074173 · Cited by 50
Dornbos, P., Koesterer, R., Ruttenburg, A., Nguyen, T., Cole, J. B., AMP-T2D-GENES Consortium, Leong, A., Meigs, J. B., Florez, J. C., Rotter, J. I., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01200-1 · Cited by 46
Rossing, P. R., Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Ruilope, L. M., Fonseca, V. A., Umpierrez, G. E., Caramori, M. L., Joseph, A., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14883 · Cited by 50
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD
Ferreira, J. P., Vasques‐Nóvoa, F., Ferrão, D., Saraiva, F. A., Falcão‐Pires, I., Neves, J. S., Sharma, A., Rossignol, P., Zannad, F. M., & Leite-Moreira, A. F. (2022) · Diabetes Care · doi:10.2337/dc21-1977 · Cited by 49
García‐Hermoso, A., Ezzatvar, Y., Huerta‐Uribe, N., Alonso-Martínez, A. M., Chueca-Guindulain, M. J., Berrade‐Zubiri, S., Izquierdo, M., & Ramírez‐Vélez, R. (2022) · European Journal of Sport Science · doi:10.1080/17461391.2022.2086489 · Cited by 57
“The American Diabetes Association (ADA) recommends the use of glycated haemoglobin (HbA1c) for the evaluation of glycaemic control in T1DM, with a target of <7% for all paediatric age groups, aiming at the prevention of future complications (Association, 2021; DiMeglio et al., 2018).”
BackgroundKong, A. P. S., Lim, S. K., Yoo, S.-H., Ji, L., Chen, L., Bao, Y., Yeoh, E. C. K., Chan, S.-P., Wang, C., Mohan, V., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110718 · Cited by 49
Criego, A. B., Carlson, A. L., Brown, S. A., Forlenza, G. P., Bode, B. W., Levy, C. J., Hansen, D. W., Hirsch, I. B., Bergenstal, R. M., Sherr, J. L., et al. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0364 · Cited by 46
Differences in U.S. Rural-Urban Trends in Diabetes ABCS, 1999–2018
Mercado, C. I., Bullard, K. M., Gregg, E. W., Ali, M. K., Saydah, S., & Imperatore, G. (2021) · Diabetes Care · doi:10.2337/dc20-0097 · Cited by 52
Boye, K. S., Lage, M. J., Thieu, V. T., Shinde, S., Dhamija, S., & Bae, J. P. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107975 · Cited by 51
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Cahn, A., Wiviott, S. D., Mosenzon, O., Goodrich, E. L., Murphy, S. A., Yanuv, I., Rozenberg, A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1744 · Cited by 45
Insulin: evolution of insulin formulations and their application in clinical practice over 100 years
Bolli, G. B., CHENG, A. Y. Y., & Owens, D. R. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01938-4 · Cited by 56
Zhang, H., Zhang, Q., Luo, D., Cai, X., Li, R., Zhang, Y., Lu, Y., Liu, J., Gu, J., & Li, M. (2022) · Journal of Clinical Nursing · doi:10.1111/jocn.16082 · Cited by 41
MOF-Based Materials for Glucose Detection
Zhang, Y., Lin, Q., Song, Y., Huang, J., Chen, M., Ouyang, R., Liu, S., & Dai, Z. (2023) · Chemosensors · doi:10.3390/chemosensors11080429 · Cited by 44
Association of the Monocyte–to–High-Density Lipoprotein Cholesterol Ratio With Diabetic Retinopathy
Tang, X., Tan, Y. C. R. S., Yang, Y., Li, M., He, X., Lü, Y., Shi, G., Zhu, Y., Nie, Y., Li, H., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.707008 · Cited by 45
Assessment of glycemia in chronic kidney disease
Hassanein, M., & Shafi, T. (2022) · BMC Medicine · doi:10.1186/s12916-022-02316-1 · Cited by 48
Biomolecular feedback controllers: from theory to applications
Filo, M., Chang, C.-H., & Khammash, M. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102882 · Cited by 47
The relationship between SGLT2 and systemic blood pressure regulation
Ahwin, P., & Martinez, D. (2024) · Hypertension Research · doi:10.1038/s41440-024-01723-6 · Cited by 49
“Hemoglobin A1c is a way of quantifying blood sugar levels by measuring the degree of glycosylated sugar in the blood for an average of three months [26, 27].”
BackgroundLin, Y. K., Richardson, C. R., Dobrin, I., DeJonckheere, M. J., Mizokami-Stout, K., Fetters, M. D., Aikens, J. E., Fisher, S. J., Ye, W., & Pop-Busui, R. (2022) · Diabetes Care · doi:10.2337/dc21-1285 · Cited by 40
Glycemic control in the critically ill: Less is more
Alhatemi, G., Aldiwani, H., Alhatemi, R., Hussein, M., Mahdai, S., & Seyoum, B. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.20171 · Cited by 53
“47 52 In RCTs, a pooled analysis of the NICE-SUGAR study 53 and the study by Mey-froidt et al 54 showed that hypoglycemia increased the odds of mortality.”
Impact of a Digital Lifestyle Intervention on Diabetes Self-Management: A Pilot Study
Bretschneider, M. P., Klásek, J., Karbanová, M., Timpel, P., Herrmann, S., & Schwarz, P. E. H. (2022) · Nutrients · doi:10.3390/nu14091810 · Cited by 39
Boureau, A., Guyomarch, B., Gourdy, P., Allix, I., Annweiler, C., Cervantes, N., Chapelet, G., Delabrière, I., Guyonnet, S., Litke, R. R., et al. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18341 · Cited by 45
Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes
Snell-Bergeon, J. K., Kaur, G., Renner, D., Akturk, H. K., Beatson, C., & Garg, S. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0328 · Cited by 40
Wu, T.-E., Su, Y., & Chen, H.-S. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110069 · Cited by 49
Yang, G., Yeung, S. L. A., & Schooling, C. M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104259 · Cited by 48
Rossing, P., Burgess, E., Agarwal, R., Anker, S. D., Filippatos, G. S., Pitt, B., Ruilope, L. M., Gillard, P., MacIsaac, R. J., Wainstein, J., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1944 · Cited by 44
Wu, H., Lau, E. S. H., Yang, A., Zhang, X., Fan, B., Ronald, C. W., Kong, A. P. S., Chow, E., So, W., Chan, J. C. N., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004173 · Cited by 44
Qu, F., Shi, Q., Wang, Y., Shen, Y., Zhou, K., Pearson, E. R., & Li, S. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002073 · Cited by 37
Cordero, C., Schneiderman, N., Llabre, M. M., Teng, Y., Daviglus, M. L., Cowie, C. C., Cai, J., Talavera, G. A., Gallo, L. C., Kaplan, R. C., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1543 · Cited by 42
Battelino, T., Danne, T., Edelman, S. V., Choudhary, P., Renard, É., Westerbacka, J., Mukherjee, B., Pilorget, V., Coudert, M., & Bergenstal, R. M. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14898 · Cited by 41
Saikat, A. S. M., Hossain, R., Mina, F. B., Das, S., Khan, I. N., Mubarak, M. S., & Islam, M. T. (2021) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-021-00193-y · Cited by 44
“Diabetes is usually associated with different degrees of reduced insulin secretion and insulin sensitivity.”
BackgroundInfluentialAssociation of Diabetes Mellitus Status and Hyperglycemia With Symptomatic Knee Osteoarthritis
Zheng, J., Huang, X., Huang, J., Meng, B., Li, F., Liu, H., Chen, L., Zhou, R., Zou, M., & Wu, X. (2022) · Arthritis Care & Research · doi:10.1002/acr.24872 · Cited by 35
Arunachalum, S., Velado, K., Vigersky, R. A., & Cordero, T. L. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221088608 · Cited by 34
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S73-S84
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4236126199
- Cited by
- 847
- References
- 118
- Citations by year
- 2026: 43 · 2025: 80 · 2024: 115 · 2023: 156 · 2022: 265 · 2021: 187 · 2020: 1
- FWCI
- 23.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic targets, diabetes management, clinical guidelines, quality of care, level of evidence, treatment goals
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.